Non-small-cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality worldwide. Despite the significant outcomes achieved with immune checkpoint blockade (ICB), used alone or in combination with chemotherapy (CT), almost half of these patients do not initially respond to this strategy (primary resistance), and furthermore, a subset of patients who initially respond, later relapse developing secondary resistance.1,2